Partners Marc J. Ross and James M. Turner Represent Tonix Pharmaceuticals in $10 Million Public Offering of Common Stock

By Sichenzia Ross Ference LLP | May 6, 2020

Press Release – New York, NY – June 23, 2016 – Securities and corporate law firm Sichenzia Ross Friedman Ference LLP is pleased to announce that the firm has represented Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP), a developer of next-generation medicines for common disorders of the central nervous system,

including fibromyalgia and post-traumatic stress disorder, in an underwritten public offering of 5,000,000 shares of its common stock. The shares were sold at a purchase price of $2.00 per share. Tonix raised $10 million in gross proceeds. Roth Capital Partners and National Securities Corporation, a wholly-owned subsidiary of National Holdings, Inc. (NASDAQ:NHLD), acted as joint book-running managers for the offering.

The Sichenzia Ross Friedman Ference LLP team was led by Partners Marc J. Ross and James M. Turner and associate Nazia Khan.

[starbox id=1]

Posted in News, Press Releases, Transactions and tagged capital markets, common stock, Equity, Public Offering, Securities Law, sichenzia ross friedman ference, srff, Tonix Pharmaceuticals, transactions-prior